Thrombolysis restores perfusion in COVID 19 hypoxia

Arachchillage DJ, Stacey A, Akor F, Scotz M, Laffan M.

COVID-19 Pandemic: Are Patients with Inflammatory Bowel Disease Really at Risk?

Hassan SA, Ezeh J.

Heparin-Induced Thrombocytopenia in COVID-19

Lingamaneni P, Gonakoti S, Moturi K, Vohra I, Zia M.

[Use of Statins, Anticoagulants, Antiaggregants and Antiarrhythmic Drugs in Patients With COVID-19. The Agreed Experts' Position of Russian Society of Cardiology, Eurasian Association of Therapists, National Society on Atherothrombosis, Societies of Experts in Urgent Cardiology, Eurasian Arrhyth

Shlyakhto YV, Arutyunov GP, Belenkov YN, Tarlovskaya EI, Konradi AO, Panchenko EP, Yavelov IS, Tereshchenko SN, Ardashev AV, Arutyunov AG, Grigorieva NY, Dzhunusbekova GA, Drapkina OM, Koziolova NA, Komarov AL, Kropacheva ES, Malchikova SV, Mitkovskaya NP, Orlova YA, Petrova MM, Rebrov AP, Sisakian H, Skibitsky VV, Sugraliyev AB, Fomin IV, Chesnikova AI, Shaposhnik II, Zhelyakov EG, Kanorskii SG, Kolotsey LV, Snezhitskiy VA.

The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience

Pesavento R, Ceccato D, Pasquetto G, Monticelli J, Leone L, Frigo A, Gorgi D, Postal A, Marchese GM, Cipriani A, Saller A, Sarais C, Criveller P, Gemelli M, Capone F, Fioretto P, Pagano C, Rossato M, Avogaro A, Simioni P, Prandoni P, Vettor R.

Anticoagulants and immunosuppressants in COVID-19: Bullets to Defeat MicroCLOTS

Turi S, Nardelli P, Landoni G.

Antiviral anticoagulation

Pryzdial ELG, Sutherland MR, Lin BH, Horwitz M.

Anticoagulation, immortality, and observations of COVID-19

Maley JH, Petri CR, Brenner LN, Chivukula RR, Calhoun TF, Vinarsky V, Hardin CC.

Spontaneous and Severe Haematomas in Patients with COVID-19 on Low- Molecular-Weight Heparin for Paroxysmal Atrial Fibrillation

Mazzitelli M, Serapide F, Tassone B, Laganà D, Trecarichi EM, Torti C.

Immune Thrombocytopenic Purpura in Patients with COVID-19

Revuz S, Vernier N, Saadi L, Campagne J, Poussing S, Maurier F.

Bivalirudin for Maintenance Anticoagulation During Venovenous Extracorporeal Membrane Oxygenation for COVID-19

Seelhammer TG, Rowse P, Yalamuri S.

[Recommendations for the use of thromboprophylaxis in hospitalized patients with COVID-19 in Argentina]

Vazquez FJ, Korin J, Baldessari EM, Capparelli FJ, Gutierrez P, Pale C, Bocanegra F, Grand B, Penchasky D, Gonzalez Alcántara MM, Prémoli MS, Tabares A, Wainsztein N, Odetto D, Vaccaro C, Martínez Aquino E, Cumpian O, Falabella V, Antuel García S, Saadi J, Siccardi M, Gándara E.

Heparin induced thrombocytopenia antibodies in COVID-19

Patell R, Khan A, Bogue T, Merrill M, Koshy A, Bindal P, Joyce R, Aird WC, Neuberg D, Bauer KA, Zwicker JI.

Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions

Kim SY, Jin W, Sood A, Montgomery DW, Grant OC, Fuster MM, Fu L, Dordick JS, Woods RJ, Zhang F, Linhardt RJ.

Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients

Zhang Y, Cao W, Jiang W, Xiao M, Li Y, Tang N, Liu Z, Yan X, Zhao Y, Li T, Zhu T.

Aortic thrombus in patients with severe COVID-19: review of three cases

de Carranza M, Salazar DE, Troya J, Alcázar R, Peña C, Aragón E, Domínguez M, Torres J, Muñoz-Rivas N.

Mortality and the use of Antithrombotic Therapies among Nursing Home Residents with COVID-19

Brouns SH, Brüggemann R, Linkens A, Magdelijns FJ, Joosten H, Heijnen R, Ten Cate-Hoek AJ, Schols J, Ten Cate H, Spaetgens B.

Anti-coagulation for COVID-19 treatment: both anti-thrombotic and anti-inflammatory?

Paar V, Wernly B, Zhou Z, Motloch LJ, Hoppe UC, Egle A, Lichtenauer M.

A possible benefit from therapeutic anticoagulation in COVID-19: the Dolo hospital experience in Veneto, Italy

Secco E, Pasqualetto MC, Bombardini T, Picano E, Rigo F.

Anticoagulation clinic drive-up service during COVID-19 pandemic in Qatar

Alhmoud E, Abdelsamad O, Soaly E, Enany RE, Elewa H.

Successful use of tPA for thrombolysis in COVID related ARDS: a case series

Goyal A, Saigal S, Niwariya Y, Sharma J, Singh P.

A Case of COVID-19 Infection With Delayed Thromboembolic Complication on Warfarin

Garg A, Goyal S, Patel P.

Heparin 2.0: A New Approach to the Infection Crisis

Seffer MT, Cottam D, Forni LG, Kielstein JT.

Lupus anticoagulant is frequent in patients with Covid-19: Response to Reply

Harzallah I, Debliquis A, Drénou B.

Mechanisms of stroke and the role of anticoagulants in COVID-19

Mishra AK, Sahu KK, Lal A, Sargent J.

A case of Covid-19 patient with acute limb ischemia and heparin resistance

Baccellieri D, Bilman V, Apruzzi L, Monaco F, D'Angelo A, Loschi D, Melissano G, Chiesa R.

Management of ST-Elevation Myocardial Infarction in the COVID-19 Era: The Role of Thrombosis and Anticoagulation Strategy

Al-Sadawi M, Mohiuddin A, Hossain N, Shaikh S, Feit A, Ramalanjaona B, Salifu MO, McFarlane SI.

COVID-19 mortality in patients on anticoagulants and antiplatelet agents

Sivaloganathan H, Ladikou EE, Chevassut T.

The utility of native MS for understanding the mechanism of action of repurposed therapeutics in COVID-19: heparin as a disruptor of the SARS-CoV-2 interaction with its host cell receptor

Yang Y, Du Y, Kaltashov IA.

Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives

Tandon R, Sharp JS, Zhang F, Pomin VH, Ashpole NM, Mitra D, Jin W, Liu H, Sharma P, Linhardt RJ.

ADL-dependency, D-Dimers, LDH and absence of anticoagulation are independently associated with one-month mortality in older inpatients with Covid-19

Bousquet G, Falgarone G, Deutsch D, Derolez S, Lopez-Sublet M, Goudot FX, Amari K, Uzunhan Y, Bouchaud O, Pamoukdjian F.

Intracranial hemorrhage complicating anticoagulant prophylactic therapy in three hospitalized COVID-19 patients

Ghani MU, Kumar M, Ghani U, Sonia F, Abbas SA.

Correction to: Heparin resistance in COVID‑19 patients in the intensive care unit

White D, MacDonald S, Bull T, Hayman M, de Monteverde-Robb D, Sapsford D, Lavinio A, Varley J, Johnston A, Besser M, Thomas W.

Current Perspectives of Anticoagulation in Patients with COVID-19

Gavioli EM, Sikorska G, Man A, Rana J, Vider E.

Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era

Rossi R, Coppi F, Talarico M, Boriani G.

Curative anticoagulation prevents endothelial lesion in COVID-19 patients

Khider L, Gendron N, Goudot G, Chocron R, Hauw-Berlemont C, Cheng C, Rivet N, Pere H, Roffe A, Clerc S, Lebeaux D, Debuc B, Veyer D, Rance B, Gaussem P, Bertil S, Badoual C, Juvin P, Planquette B, Messas E, Sanchez O, Hulot JS, Diehl JL, Mirault T, Smadja DM.

COVID-19 anticoagulation recommendations in children

Loi M, Branchford B, Kim J, Self C, Nuss R.

The Role of Anticoagulation in COVID-19-Induced Hypercoagulability

Rico-Mesa JS, Rosas D, Ahmadian-Tehrani A, White A, Anderson AS, Chilton R.

Antithrombotic Therapies in COVID-19 Disease: a Systematic Review

Maldonado E, Tao D, Mackey K.

Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced Coagulopathy

Turshudzhyan A.

Acute cor pulmonale from saddle pulmonary embolism in a patient with previous Covid-19 - should we prolong prophylactic anticoagulation?

Ali S, Pappachan JM, Mathew S.

Fibrinolysis and COVID-19: a plasmin paradox

Medcalf RL, Keragala CB, Myles PS.

Fibrinolytic therapy for refractory COVID-19 acute respiratory distress syndrome: Scientific rationale and review

Barrett CD, Moore HB, Moore EE, McIntyre RC, Moore PK, Burke J, Hua F, Apgar J, Talmor DS, Sauaia A, Liptzin DR, Veress LA, Yaffe MB.

Using heparin molecules to manage COVID-2019

Liu J, Li J, Arnold K, Pawlinski R, Key NS.

Emergence of institutional antithrombotic protocols for coronavirus 2019

Cohoon KP, Mahé G, Tafur AJ, Spyropoulos AC.

Rethinking COVID-19 'pneumonia' - is this primarily a vaso-occlusive disease, and can early anticoagulation save the ventilator famine?

Low TT, Cherian R, Lim SL, Chandra B, Tung ML, Kumar SK, Lye P, Chin Xin Yi A, Teo L, Tay EL.

COVID-19 HASTENS A STRUCTURAL SHIFT IN THE LCD MARKET

Dickson G.

Should lCU COVID-19 patients empirically receive therapeutic doses of anticoagulant?

Di Perri G.

Should lCU COVID-19 patients empirically receive therapeutic doses of anticoagulant?

Piazza O.

The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner

Yamamoto M, Kiso M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Takeda M, Kinoshita N, Ohmagari N, Gohda J, Semba K, Matsuda Z, Kawaguchi Y, Kawaoka Y, Inoue JI.

Pulmonary Artery Embolism in COVID-19 Despite Thrombosis Prophylaxis

Geerdes-Fenge HF, Reisinger EC, Arndt H.

Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment

Aryal MR, Gosain R, Donato A, Pathak R, Bhatt VR, Katel A, Kouides P.

COVID-19: opening a new paradigm in thromboprophylaxis for critically ill patients?

Ferrandis R, Llau JV, Quintana M, Sierra P, Hidalgo F, Cassinello C, Gómez-Luque A.

COVID-19 Experience in Hemodialysis Patients: A Cue for Therapeutic Heparin-Based Strategies?

Pisani A, Rizzo M, Angelucci V, Riccio E.

Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis

Rivas-Pollmar MI, Álvarez-Román MT, Butta-Coll NV, Martín Salces M, García-Barcenilla S, Jiménez-Yuste V.

Low molecular weight heparins in COVID-19 patients: beware of augmented renal clearance!

Tomasa-Irriguible TM, Martínez-Vega S, Mor-Marco E, Herraiz-Ruiz A, Raguer-Pardo L, Cubells-Larrosa C.

Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities

Hippensteel JA, LaRiviere WB, Colbert JF, Langouët-Astrié CJ, Schmidt EP.

Anticoagulation with Argatroban in patients with acute antithrombin deficiency in severe COVID -19

Arachchillage DJ, Remmington C, Rosenberg A, Xu T, Passariello M, Hall D, Laffan AM, Patel BV.

Guidance for anticoagulation management in venous thromboembolism during the coronavirus disease 2019 (COVID-19) pandemic in Poland: an expert opinion of the Section on Pulmonary Circulation of the Polish Cardiac Society

Kosior DA, Undas A, Kopeć G, Hryniewiecki T, Torbicki A, Mularek-Kubzdela T, Windyga J, Pruszczyk P.

Managing anticoagulation in the COVID-19 era between lockdown and reopening phases

Poli D, Tosetto A, Palareti G, Barcellona D, Ciampa A, Grandone E, Manotti C, Moia M, Squizzato A, Toschi V, Testa S; On the behalf of Italian Federation of Anticoagulation Clinics (FCSA).

Thromboprophylaxis in COVID-19: Anti-FXa - The Missing Factor?

Dutt T, Simcox D, Downey C, McLenaghan D, King C, Gautam M, Lane S, Burhan H.

Pharmacists reinventing their roles to effectively respond to COVID-19: a global report from the international pharmacists for anticoagulation care taskforce (iPACT)

Alves da Costa F, Lee V, Leite SN, Murillo MD, Menge T, Antoniou S.

Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report

Papamichalis P, Papadogoulas A, Katsiafylloudis P, Skoura AL, Papamichalis M, Neou E, Papadopoulos D, Karagiannis S, Zafeiridis T, Babalis D, Komnos A.

Is there a rationale for heparin use among severe COVID-19 patients?

Savioli F.

The association between treatment with heparin and survival in patients with Covid-19

Ayerbe L, Risco C, Ayis S.

Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study

Russo V, Di Maio M, Attena E, Silverio A, Scudiero F, Celentani D, Lodigiani C, Di Micco P.

Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin

Thachil J.

A matter of time: duration and choice of venous thromboprophylaxis in patients diagnosed with COVID-19

Kumar P, Mediwake R, Rhead C.

Heparin-Related Major Bleeding in Covid-19-Positive Patient: Perspective from the Outbreak

Lucatelli P, De Rubeis G, Citone M, Lucarelli NM, Pasqualini V, Sturiale M, Giuliani S, Rosati M, Ceccherini C, Corona M, Mosconi C, Utili A, Argirò R.

Thromboprophylaxis for medical inpatients with COVID-19

Dalager-Pedersen M, Bodilsen J.

Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial"

Marietta M, Tripodi A.

Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial

Cattaneo M, Morici N.

COVID-19, thromboembolic risk and thromboprophylaxis: learning lessons from the bedside, awaiting evidence

Coppola A, Lombardi M, Tassoni MI, Carolla G, Tala M, Morandini R, Paoletti O, Testa S.

Thrombosis and coagulopathy in COVID-19 patients requiring extracorporeal membrane oxygenation

Yusuff H, Zochios V, Brodie D.

Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum

Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, Dager WE, Deitelzweig SB, Ellsworth S, Garcia D, Kaatz S, Minichiello T.

Covid-19 and thrombosis: what do we know about the risks and treatment?

Wise J.

Is Biologic Treatment of Hidradenitis Suppurativa During the COVID-19 Pandemic Different from Psoriasis Biologic Treatment?

Rosi E, Pimpinelli N, Prignano F.

Anti-Coagulant and Anti-Platelet Therapy in the COVID-19 Patient: A Best Practices Quality Initiative Across a Large Health System

Watson RA, Johnson DM, Dharia RN, Merli GJ, Doherty JU.

Heparin - an old drug with multiple potential targets in Covid-19 therapy

Lindahl U, Li JP.

A perfect storm: Root cause analysis of supra-therapeutic anticoagulation with vitamin K antagonists during the COVID-19 pandemic

Speed V, Patel RK, Byrne R, Roberts LN, Arya R.

Fibrinolysis Shutdown Correlates to Thromboembolic Events in Severe COVID-19 Infection

Wright FL, Vogler TO, Moore EE, Moore HB, Wohlauer MV, Urban S, Nydam TL, Moore PK, McIntyre RC Jr.

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

George PM, Wells AU, Jenkins RG.

Pulmonary fibrosis secondary to COVID-19: a call to arms?

Spagnolo P, Balestro E, Aliberti S, Cocconcelli E, Biondini D, Casa GD, Sverzellati N, Maher TM.

Correction to: Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies and the lack of guidelines.

Porfidia A, Pola R.

Thrombocytopenia and coagulation disorders due to COVID 19 infection with concomitant cardiovascular diseases requiring anti-platelet and anticoagulant therapy, which strategy?

Buioni D, Nardi P, Ruvolo G.

Problems related with anticoagulant usage during COVID-19 outbreak

Doganci S, Yildirim AK.

Safe tracheotomy for patients with COVID-19.

Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients.

Menezes-Rodrigues FS, Padr√£o Tavares JG, Pires de Oliveira M, Guzella de Carvalho R, Ruggero Errante P, Omar Taha M, Fagundes DJ, Caricati-Neto A.

Prophylactic anticoagulant therapy for reducing the risk of stroke and other thrombotic events in COVID-19 patients.

Fibrinolysis in COVID-19 patients with hemodynamic unstable acute pulmonary embolism: yes or no?

Roncon L, Zuin M, Zonzin P.

Reply to Rheumatologists' perspective on coronavirus disease 19: is heparin the dark horse for COVID-19?

Ahmed S, Anirvan P.

Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19.

The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19.

Canonico ME, Siciliano R, Scudiero F, Sanna GD, Parodi G.

Response to "Lupus anticoagulant is frequent in patients with Covid-19".

Tang N.

Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment.

Roncon L, Zuin M, Rigatelli G.

Arterial thromboembolic complications in COVID-19 in low risk patients despite prophylaxis.

Griffin DO, Jensen A, Khan M, Chin J, Chin K, Parnell R, Awwad C, Patel D.

Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic.

Price E, MacPhie E, Kay L, Lanyon P, Griffiths B, Holroyd C, Abhishek A, Youngstein T, Bailey K, Clinch J, Shaikh M, Rivett A.

Global rheumatology in the time of COVID-19.

Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies.

Porfidia A, Pola R.

Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients.

Lacour T, Semaan C, Genet T, Ivanes F.

Anticoagulation in COVID-19.

Atallah B, Mallah SI, AlMahmeed W.

Why Fibrinolytic Therapy for STEMI in The COVID-19 Pandemic is Not Your New Best Friend.

Kirtane AJ, Bangalore S.

Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.

Whyte CS, Morrow GB, Mitchell JL, Chowdary P, Mutch NJ.

Type and dose of heparin in COVID-19.

Thachil J, Tang N, Gando S, Falanga A, Levi M, Clark C, Iba T, Cattaneo M.

[Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology].

Vivas D, Roldán V, Esteve-Pastor MA, Roldán I, Tello-Montoliu A, Ruiz-Nodar JM, Cosín-Sales J, María Gámez J, Consuegra L, Luis Ferreiro J, Marín F, Arrarte V, Anguita M, Cequier Á, Pérez-Villacastín J.

Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action.

Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K.

Potential of Heparin and Nafamostat Combination Therapy for COVID-19.

Asakura H, Ogawa H.

Response to 'Reply to Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy'.

Tang N.

Reply to Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Coto-Hern√°ndez R, F√°bregas Ruano MT.

Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients.

Testa S, Paoletti O, Giorgi-Pierfranceschi M, Pan A.

COVID-19 and Kawasaki Disease: Novel Virus and Novel Case.

Jones VG, Mills M, Suarez D, Hogan CA, Yeh D, Bradley Segal J, Nguyen EL, Barsh GR, Maskatia S, Mathew R.

The versatile heparin in COVID-19.

Thachil J.

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z.